ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Organocatalytic C─O Bond Cleavage and Asymmetric Transformations via [1,3]-Sigmatropic Rearrangement.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Organocatalytic C─O Bond Cleavage and Asymmetric Transformations via [1,3]-Sigmatropic Rearrangement.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Here, an organocatalytic asymmetric [1,3]-sigmatropic rearrangement process for aryl ether insertion through C─O bond cleavage and downstream transformation is reported, enabling the practical and atom-economic synthesis of diverse valuable chiral benzofuran derivatives bearing a quaternary carbon stereocenter. The reaction shows a wide substrate scope, yielding moderate to good products with excellent enantioselectivity and diastereoselectivity (up to >99% ee and >99:1 d.r.). Initial biological activity tests suggest that the resulting enantioenriched benzofuran products hold potential as anticancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.